BR112022010672A2 - Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica - Google Patents

Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica

Info

Publication number
BR112022010672A2
BR112022010672A2 BR112022010672A BR112022010672A BR112022010672A2 BR 112022010672 A2 BR112022010672 A2 BR 112022010672A2 BR 112022010672 A BR112022010672 A BR 112022010672A BR 112022010672 A BR112022010672 A BR 112022010672A BR 112022010672 A2 BR112022010672 A2 BR 112022010672A2
Authority
BR
Brazil
Prior art keywords
liver disease
fatty liver
methods
active agents
treatment
Prior art date
Application number
BR112022010672A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Casey John Jr
Arthur Berry David
F Briggs Timothy
Buckbinder Leonard
Kim Mi-Jeong
Liang Anna
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of BR112022010672A2 publication Critical patent/BR112022010672A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112022010672A 2019-12-05 2020-12-04 Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica BR112022010672A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US202063074785P 2020-09-04 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
BR112022010672A2 true BR112022010672A2 (pt) 2022-08-16

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010672A BR112022010672A2 (pt) 2019-12-05 2020-12-04 Agentes ativos acilados e métodos de seu uso para o tratamento de distúrbios metabólicos e doença hepática gordurosa não alcoólica

Country Status (8)

Country Link
US (1) US20220296563A1 (enExample)
EP (1) EP4069209A4 (enExample)
JP (1) JP2023504547A (enExample)
CN (1) CN114901267A (enExample)
AU (1) AU2020396554A1 (enExample)
BR (1) BR112022010672A2 (enExample)
CA (1) CA3163342A1 (enExample)
WO (1) WO2021113620A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
FR2720936B1 (fr) * 1994-06-08 1997-04-30 Synthelabo Poudres à base de métoclopramide et de paracétamol ou de dérivés d'acide acétylsalicylique.
MX9704079A (es) * 1994-12-01 1997-12-31 Cibus Pharmaceutical Inc Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores.
DE19726871C1 (de) * 1997-06-24 1999-03-04 Werner Kreutz Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US20080114075A1 (en) * 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
EP2588108A2 (en) * 2010-07-02 2013-05-08 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
JP2021528385A (ja) * 2018-06-05 2021-10-21 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 自己免疫障害を治療するためのアシル化活性剤およびその使用方法
EP3801496A4 (en) * 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. SUBSTANCES AND METHODS OF USE FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOL FATTY LIVER
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Also Published As

Publication number Publication date
CA3163342A1 (en) 2021-06-10
EP4069209A1 (en) 2022-10-12
WO2021113620A1 (en) 2021-06-10
CN114901267A (zh) 2022-08-12
US20220296563A1 (en) 2022-09-22
AU2020396554A1 (en) 2022-07-07
EP4069209A4 (en) 2024-04-10
JP2023504547A (ja) 2023-02-03
WO2021113620A8 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
CO2021000447A2 (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso
BR112021022796A2 (pt) Inibidores de inflamassoma de nlrp3
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CL2024001723A1 (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
CO2026004964A2 (es) Moduladores de kras
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
CO2024013744A2 (es) Moduladores de nlrp3
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112018072339A2 (pt) tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados
CO2022014499A2 (es) Moduladores de nlrp3
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
MX2021008941A (es) Moduladores gpr35.
CL2021000282A1 (es) Inhibidores de ckd8/19

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]